Market Cap 10.74B
Revenue (ttm) 2.76B
Net Income (ttm) -1.03B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 156.08
Profit Margin -37.29%
Debt to Equity Ratio 0.00
Volume 1,889,400
Avg Vol 3,148,088
Day's Range N/A - N/A
Shares Out 189.32M
Stochastic %K 96%
Beta 1.24
Analysts Strong Sell
Price Target $65.59

Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic,...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 608 284 5700
Address:
5505 Endeavor Lane, Madison, United States
epicsw
epicsw Oct. 7 at 1:57 AM
$EXAS Sure looks like a double-bottom on the year-to-date and 1-year charts to me. Pretty obvious, no?
1 · Reply
WOLFSTREET
WOLFSTREET Oct. 5 at 8:04 PM
$EXAS long overdue for a 2X run, started just under $50 from where I stand
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 10:02 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $EXAS Current Share Price: $56.72 Contracts: $EXAS January 15, 2027 $58 Calls Scale in: $11.07- $13.53 Scale out: $17.22-$22.14 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 12:24 AM
Enter: $EXAS OCT 24 2025 $57 CALLS Buy in Price: $1.90 - $2.40 Take Profit: $4.43 Stop Bleeding: $1.67 ROI Potential: 133% Exit Within: 325 Minutes https://moneygroup.us/alerts
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Oct. 3 at 7:53 PM
$EXAS fantastic
2 · Reply
IN0V8
IN0V8 Oct. 3 at 4:37 PM
$EXAS Buy Barclays raises target price to $65 from $55
0 · Reply
healthcareguru
healthcareguru Oct. 3 at 3:23 PM
$GRAL short the trash…MCED is the future, but their test is inferior, $GH & $EXAS will crush them, and they’re hemorrhaging cash…more dilution is coming near-term. Back to <$50. 👎🐺
1 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 1:03 PM
$EXAS: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $60 Exp on 11/21/2025 with Premium of $32K and showing BULLISH Sentiment
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:04 PM
Barclays has adjusted their stance on Exact Sciences ( $EXAS ), setting the rating to Overweight with a target price of 55 → 65.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 7:03 AM
$EXAS: Unusual Options Activity Alerted CALL flow observed 44x contracts at Strike price of $47.5 Exp on 10/17/2025 with Premium of $28K and showing NEUTRAL Sentiment
1 · Reply
Latest News on EXAS
Exact Sciences' Clear Expansion Path: Why Choose To Buy

Sep 25, 2025, 5:07 AM EDT - 11 days ago

Exact Sciences' Clear Expansion Path: Why Choose To Buy


Exact Sciences CEO on Launch of Multi-Cancer Blood Test

Sep 15, 2025, 3:30 PM EDT - 21 days ago

Exact Sciences CEO on Launch of Multi-Cancer Blood Test


Exact Sciences to Participate in September Investor Conferences

Aug 19, 2025, 6:00 AM EDT - 6 weeks ago

Exact Sciences to Participate in September Investor Conferences


Exact Sciences Announces Second Quarter 2025 Results

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Exact Sciences Announces Second Quarter 2025 Results


Exact Sciences Schedules Second Quarter 2025 Earnings Call

Jul 14, 2025, 6:00 AM EDT - 3 months ago

Exact Sciences Schedules Second Quarter 2025 Earnings Call


Exact Sciences to Participate in June Investor Conference

May 27, 2025, 4:05 PM EDT - 4 months ago

Exact Sciences to Participate in June Investor Conference


Exact Sciences Earns 2025 Great Place To Work® Certification™

May 12, 2025, 10:00 AM EDT - 5 months ago

Exact Sciences Earns 2025 Great Place To Work® Certification™


Exact Sciences to Participate in May Investor Conference

May 2, 2025, 6:00 AM EDT - 5 months ago

Exact Sciences to Participate in May Investor Conference


Exact Sciences Announces First-Quarter 2025 Results

May 1, 2025, 4:05 PM EDT - 5 months ago

Exact Sciences Announces First-Quarter 2025 Results


Exact Sciences Schedules First Quarter 2025 Earnings Call

Apr 1, 2025, 6:00 AM EDT - 6 months ago

Exact Sciences Schedules First Quarter 2025 Earnings Call


Exact Sciences to Participate in March Investor Conferences

Feb 24, 2025, 6:00 AM EST - 8 months ago

Exact Sciences to Participate in March Investor Conferences


Exact Sciences Announces Fourth Quarter 2024 Results

Feb 19, 2025, 4:05 PM EST - 8 months ago

Exact Sciences Announces Fourth Quarter 2024 Results


Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

Feb 3, 2025, 6:00 AM EST - 8 months ago

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call


Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

Jan 12, 2025, 7:00 PM EST - 9 months ago

Exact Sciences Announces Preliminary Fourth Quarter 2024 Results


epicsw
epicsw Oct. 7 at 1:57 AM
$EXAS Sure looks like a double-bottom on the year-to-date and 1-year charts to me. Pretty obvious, no?
1 · Reply
WOLFSTREET
WOLFSTREET Oct. 5 at 8:04 PM
$EXAS long overdue for a 2X run, started just under $50 from where I stand
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 10:02 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $EXAS Current Share Price: $56.72 Contracts: $EXAS January 15, 2027 $58 Calls Scale in: $11.07- $13.53 Scale out: $17.22-$22.14 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 12:24 AM
Enter: $EXAS OCT 24 2025 $57 CALLS Buy in Price: $1.90 - $2.40 Take Profit: $4.43 Stop Bleeding: $1.67 ROI Potential: 133% Exit Within: 325 Minutes https://moneygroup.us/alerts
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Oct. 3 at 7:53 PM
$EXAS fantastic
2 · Reply
IN0V8
IN0V8 Oct. 3 at 4:37 PM
$EXAS Buy Barclays raises target price to $65 from $55
0 · Reply
healthcareguru
healthcareguru Oct. 3 at 3:23 PM
$GRAL short the trash…MCED is the future, but their test is inferior, $GH & $EXAS will crush them, and they’re hemorrhaging cash…more dilution is coming near-term. Back to <$50. 👎🐺
1 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 1:03 PM
$EXAS: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $60 Exp on 11/21/2025 with Premium of $32K and showing BULLISH Sentiment
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:04 PM
Barclays has adjusted their stance on Exact Sciences ( $EXAS ), setting the rating to Overweight with a target price of 55 → 65.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 7:03 AM
$EXAS: Unusual Options Activity Alerted CALL flow observed 44x contracts at Strike price of $47.5 Exp on 10/17/2025 with Premium of $28K and showing NEUTRAL Sentiment
1 · Reply
Woodman7
Woodman7 Oct. 1 at 6:31 PM
$CLNN $EXAS $ILMN $PACB - my health care stocks seem like a Good place to be today!
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 1 at 6:26 PM
$EXAS see YO at a HUNDO
0 · Reply
bearcreekzeke
bearcreekzeke Oct. 1 at 3:36 PM
1 · Reply
ManyThanks212
ManyThanks212 Sep. 30 at 11:11 PM
0 · Reply
thingkfast
thingkfast Sep. 30 at 7:40 PM
$EXAS bit different outlook from just a few months ago. Also, Guardant announcing they are launching their own multi cancer test next month. This will be interesting!
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Sep. 30 at 7:21 PM
$EXAS massive potential here. 1 hundo coming imo.
3 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 30 at 3:58 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $EXAS Current Share Price: $53.37 Contracts: $EXAS January 15, 2027 $55 Calls Scale in: $10.64- $13.01 Scale out: $16.55-$21.29 Can Easily Capture: 60% ROI Blended DTE: 473 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
StockWizardSupreme
StockWizardSupreme Sep. 29 at 4:36 AM
$BIAF Cologuard ($EXAS ) is valued around $10B. Cologuard is a noninvasive test for colorectal cancer screening with 92% sensitivity. I don’t see why CyPath wouldn’t be valued near the same. It is a noninvasive test for lung cancer screening and also has 92% sensitivity. BIAF is currently sitting with a $5 million market cap. If they were to go to $10B market cap that would be 2000x. Just some food for thought.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 29 at 1:23 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $EXAS Current Share Price: $53.57 Contracts: $EXAS January 15, 2027 $55 Calls Scale in: $10.82- $13.23 Scale out: $16.84-$21.64 Can Easily Capture: 60% ROI Blended DTE: 474 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Doozio
Doozio Sep. 27 at 4:11 PM
$EXAS QUAD weeks tight so let da 🧠 spread during 🐒🍌🧠⏰♾️.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 27 at 10:23 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $EXAS Current Share Price: $54.03 Contracts: $EXAS January 15, 2027 $55 Calls Scale in: $10.71- $13.09 Scale out: $16.66-$21.42 Can Easily Capture: 60% ROI Blended DTE: 476 Days | Join Elites here: https://liquidtheta.com
0 · Reply
topstockalerts
topstockalerts Sep. 26 at 5:02 PM
Guardant Health will launch its Shield multi-cancer blood test next month, aiming to detect various cancers early using AI. The company expects the test’s market could expand to $300 billion by identifying early signals for hundreds of diseases beyond cancer. It also anticipates achieving free-cash-flow positivity by 2028, with annual revenue growing 34% to $2.2 billion. Shield, already FDA-approved for early colorectal cancer detection, will allow doctors and patients to receive results for additional cancers starting in October. Pricing is expected to fall below $1,000, with Medicare reimbursing $1,500, potentially driving sales above $500 million by 2028. Guardant leverages AI and a biobank of over one million cancer cases to expand detection beyond cancer to organs including the brain, heart, lungs, and liver. Analysts see potential annual sales of $50 billion if cancers are caught early. $GH $EXAS $GRAL
0 · Reply